scholarly journals PD33-05 THE PROMISE AND DISAPPOINTMENT OF SEQUENTIAL THERAPY AFTER NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER: UPDATED RESULTS AND LONG-TERM FOLLOW-UP

2016 ◽  
Vol 195 (4S) ◽  
Author(s):  
Stanley Yap ◽  
Neil Pugashetti ◽  
Thenappan Chandrasekar ◽  
Marc Dall'Era ◽  
Christopher Evans ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Sequential Therapy ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Long Term Follow Up ◽  
Muscle Invasive

Long-term follow-up of TaG1 non–muscle-invasive bladder cancer

2015 ◽  
Vol 33 (1) ◽  
pp. 20.e1-20.e7 ◽  
Author(s):  
Pierre Olivier Bosset ◽  
Yann Neuzillet ◽  
Xavier Paoletti ◽  
Vincent Molinie ◽  
Henry Botto ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Muscle Invasive Bladder Cancer ◽  
Long Term Follow Up ◽  
Muscle Invasive

scholarly journals Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Christel Mathis ◽  
Isabelle Lascombe ◽  
Franck Monnien ◽  
Hugues Bittard ◽  
François Kleinclauss ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Progression ◽  
Invasive Bladder Cancer ◽  
Down Regulation ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Neoadjuvant chemotherapy in muscle invasive bladder cancer: Real world data on safety and outcome.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17036-e17036
Author(s):  
Sree Vamsee Chetana Panthula ◽  
Arun Philip ◽  
Pavithran Keechilat ◽  
Wesley Mannirathil Jose
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Invasive Bladder Cancer ◽  
Definitive Treatment ◽  
Muscle Invasive Bladder Cancer ◽  
Female Ratio ◽  
Radiological Response ◽  
Muscle Invasive

e17036 Background: The standard treatment for Muscle Invasive bladder cancer (MIBC),Radical Cystectomy and Neoadjuvant chemotherapy (NACT) has shown to improve survival. Data from Indian population is scarce, and we sought to explore the efficacy, tolerability and factors affecting the outcome of Neoadjuvant chemotherapy in our population. Methods: This was a Retrospective Observational study conducted at a tertiary care centre. Patients of MIBC treated between 2008 and 2019 were included in the analysis. The NACT consisted of Gemcitabine + Cisplatin (GC) or Gemcitabine + Carboplatin (GCa). The prognostic significance of the various clinico-laboratory parameters was assessed by the log rank test. The survival analysis was done by the Kaplan Meier method. Results: Total of 40 patients received NACT from 2008-2019. The median age of study group was 62 years. Male to Female ratio was 5:1. Out of 40 patients, 26 were treated with GC and the remaining 14 received GCa. Majority (80%) patients were administered either 3 or 4 cycles of NACT. Among 18 patients who demonstrated good radiological response after NACT completion, 13 had received Cisplatin. After NACT, 32 (80%) underwent Radical Cystectomy and 3 were treated with CTRT. The remaining 5 did not receive definitive treatment. Pathological complete response (PCR) was achieved in 10 out of 32 patients (31%). Out of 10 patients with PCR, 9 belonged to Cisplatin group and only 1 in Carboplatin group. In patients with PCR, 80% remained progression free at last follow up. Grade 3/4 toxicities were minimal. However, achieving a pathological CR did not translate into significant survival benefit in our study (p value 0.10). Median follow up time and overall survival for the cohort was 29.5 and 54 months respectively. Conclusions: Gemcitabine/Cisplatin as NACT resulted in superior radiological response, PCR, PFS and OS when compared to Gemcitabine/Carboplatin in MIBC. This regimen is well tolerated and we advocate for further prospective studies with GC in this setting. [Table: see text]

scholarly journals Differential Prognosis and Response of Denovo vs. Secondary Muscle-Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2496
Author(s):  
Mario Pones ◽  
David D’Andrea ◽  
Keiichiro Mori ◽  
Mohammad Abufraj ◽  
Marco Moschini ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Survival Data ◽  
Invasive Bladder Cancer ◽  
Cochrane Library ◽  
Muscle Invasive Bladder Cancer ◽  
Starting Point ◽  
Subgroup Analyses ◽  
Muscle Invasive

To evaluate oncological outcomes of primary versus secondary muscle-invasive bladder cancer treated with radical cystectomy. Medline, Embase, Scopus and Cochrane Library were searched for eligible studies. Hazard ratios for overall survival (OS), cancer specific survival (CSS) and progression free survival (PFS) were calculated using survival data extracted from Kaplan-Meier curves. A total of 16 studies with 5270 patients were included. Pooled analysis showed similar 5-year and 10-year OS (HR 1, p = 0.96 and HR 1, p = 0.14) and CSS (HR 1.02, p = 0.85 and HR 0.99, p = 0.93) between primMIBC and secMIBC. Subgroup analyses according to starting point of follow-up and second-look transurethral resection revealed similar results. Subgroup analyses of studies in which neoadjuvant chemotherapy was administered demonstrated significantly worse 5-year CSS (HR 1.5, p = 0.04) but not 10-year CSS (HR 1.36, p = 0.13) in patients with secMIBC. Patients with secMIBC had significantly worse PFS at 5-year (HR 1.41, p = 0.002) but not at 10-year follow-up (HR 1.25, p = 0.34). This review found comparable oncologic outcomes between primMIBC and secMIBC patients treated with RC regarding OS and CSS. Subgroup analysis showed worse 5-year CSS but not 10-year CSS for neoadjuvant chemotherapy in the secMIBC group. Prospective clinical trials incorporating molecular markers, that allow precise risk stratification of secMIBC and further research uncovering underlying molecular and clinical drivers of the heterogeneous group of secMIBC is needed.

Sign in / Sign up

Export Citation Format

Share Document